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Radiotherapy (RT) is often employed in patients with acromegaly refractory to medical and/or surgical interventions in order to
prevent tumour regrowth and normalize elevated GH and IGF-I levels. It achieves tumour control and hormone normalization
up to 90% and 70% of patients at 10–15 years. Despite the excellent tumour control, conventional RT is associated with a
potential risk of developing late toxicity, especially hypopituitarism, and its role in the management of patients with GH-secreting
pituitary adenomas remains a matter of debate. Stereotactic techniques have been developed with the aim to deliver more localized
irradiation and minimize the long-term consequences of treatment, while improving its eﬃcacy. Stereotactic irradiation can be
given in a single dose as stereotactic radiosurgery (SRS) or in multiple doses as fractionated stereotactic radiotherapy (FSRT). We
have reviewed the recent published literature on stereotactic techniques for GH-secreting pituitary tumors with the aim to deﬁne
the eﬃcacy and potential adverse eﬀects of each of these techniques.
1.Introduction
GH-secreting pituitary adenoma is responsible for acromeg-
aly, a disorder characterized by signiﬁcant morbidity and
mortality due to musculoskeletal, cardiovascular, metabolic,
and pulmonary complications [1, 2].
Surgery, radiotherapy (RT), and medical therapies,
including dopamine agonists, somatostatin-receptor ligands,
and the GH-receptor antagonist pegvisomant are available
treatments for patients with GH-secreting pituitary adeno-
mas. Transsphenoidal surgery is often employed in the initial
management of acromegaly. Remission of disease is achieved
in up to 60% of patients [3] with a low incidence of surgical
complicationsandsigniﬁcantimprovementofmetabolicand
cardiovascular dysfunctions [4, 5]. Somatostatin analogs are
as a f ea n de ﬀective treatment for GH-secreting adenomas,
resulting in a normalization of GH/IGF-I hypersecretion in
approximately 60–70% of patients [6]. RT is recommended
only for patients with persistent active disease after surgery
and/or during medical therapy, being able in normalizing
GH/IGF-I in up to 70% of patients 10–15 years after RT in
several series [7–10]. However, eﬃcacy and potential toxicity
of RT remain matter of debate.
More recently, stereotactic radiation techniques have
been employed in patients with GH-secreting pituitary
adenomastodelivermorelocalizedirradiationwithasteeper
dose gradient between the tumor and the surrounding nor-
mal tissue in order to minimize radiation-induced toxicity
while improving its eﬀectiveness [11]. The techniques either
involve photon energy from multiple cobalt 60 radiation
sources (gamma knife) or a modiﬁed linear accelerator
(LINAC) and are given as a single fraction stereotactic radio-
surgery (SRS) or as fractionated stereotactic radiotherapy
(FSRT).
In this paper, we present a critical analysis of the
more recent available literature on fractionated stereotactic
radiotherapy and radiosurgery for GH-secreting pituitary
adenomas, in an attempt to deﬁne the eﬃcacy, safety, and
role of the individual stereotactic techniques.
2. Stereotactic Techniques
2.1. Stereotactic Radiosurgery (SRS). SRS using either a mul-
tiple cobalt-60 gamma radiation-emitting sources gamma
knife (GK) or a LINAC has been extensively employed in
the last two decades in patients with small brain tumors2 International Journal of Endocrinology
[12]. During SRS, patients are usually immobilized in a ﬁxed
frame with a positioning accuracy <1mm, and a single,
high dose of radiation is delivered to a well-deﬁned tumor
volume. The GK system is the most widely radiosurgical
technique used for treating brain tumors and consists of
an array of 201 cobalt-60 sources that are arranged in a
hemisphere and focused with a collimator helmet on a
single or multiple points termed as isocenters. The best dose
conformality is achieved by changing the number and the
distribution of isocenters and the beam size by variation
of collimator apertures. This results in a sharp-step-dose
gradient between the tumor and the surrounding normal
tissue, and small target may receive high doses while adjacent
radiation-sensitive structures will receive negligible doses.
Instead of using an array of cobalt sources, Linac SRS
utilizes X-rays which are derived from colliding accelerated
electrons with a target metal. The treatment is delivered with
the use of multiple arcs or beams resulting in high-dose dif-
ferential between the target and normal brain tissue. Isodose
gradientsareimprovedbytheuseofmultipleisocentreplans,
intensity modulation of the beams, restriction of gantry
angles and arc lengths, and microcollimation. Regardless
the superiority in terms of dose delivery and distribution
claimed for each of these techniques, the reported clinical
eﬃcacy and toxicity are similar.
CyberKnife (Accuray, Sunnyvale, CA) is a relatively new
technological device which combines a mobile linear acceler-
atormountedonaroboticarmwithanimage-guidedrobotic
system. The system allows for frameless SRS achieving the
sameleveloftargetingprecisionasframe-basedSRS.Patients
are ﬁxed in a thermoplastic mask, and the treatment can be
delivered in form of hypofractionated regimen in patients
with tumors involving the optic apparatus and who are not
suitable for SRS [13, 14].
Particleradiationhasbeenalsoappliedsuccessfullyinthe
treatment of pituitary adenomas. The physical properties of
proton irradiation can oﬀer superior conformality in dose
distribution when compared to photons, and the advantage
becomes more apparent for large volumes [15]. Proton
therapy can be delivered as SRS or as FSRT with the
same immobilization systems and target accuracy of photon
techniques. Although potential beneﬁt that may derives by
the irradiation of larger tumors located close to critical
anatomic structure, the superiority of protons in terms of
clinical eﬃcacy and reduced toxicity remains to be proven.
2.2. Fractionated Stereotactic Radiotherapy (FSRT). FSRT is
a stereotactic technique in which a variable number of
fractions are delivered to a target by a modiﬁed LINAC-
based accelerator. Although FSRT uses the same planning
system as SRS, patients undergoing FSRT are usually immo-
bilized in a high-precision frameless stereotactic ﬁxation
system,includinginfraredcameraguidance[16],dental[17],
implanted ﬁducial markers [18], and mask ﬁxation system
[19, 20] with a reported accuracy of 1–3mm. Thus, FSRT
combines the precision of stereotactic technique with the
biological advantages of fractionation. Large single doses of
radiation are in fact more toxic to normal brain structures
than similar doses given in a fractionated manner. FSRT is
usually administered in 25–30 daily fractions of 1.8–2Gy as
for conventional RT; however, hypofractionated stereotactic
radiotherapy (HSRT) in which a total dose of 20–40Gy is
delivered in 3–7 fractions can be used in selected patients.
ThedecisiononwhethertouseSRSorFSRTforpituitary
tumors mainly depends on the volume of the target lesion
and its proximity to sensitive structures. SRS is usually
oﬀered to patients with relatively small adenomas not in
close proximity of the optic apparatus. A well-deﬁned dose-
dependentriskofradiationopticneuropathyexistsfollowing
single doses of irradiation, and current practice of SRS
aims to avoid irradiating the optic apparatus to single
doses beyond 10Gy [21, 22]. Leber et al. [21]r e p o r t e d
on 66 patients receiving RS for parasellar tumors. Optic
neuropathy occurred in 0%, 26%, and 78% of patients
receiving doses less than 10Gy, 10 to 15Gy, and more than
15Gy to the optic apparatus, respectively. Staﬀord et al. [22]
reportedanincidenceofopticneuropathyof2%inaseriesof
215 patients after treatment with SRS for skull base tumors.
The rates of optic neuropathy were less than 2% for doses
between 8 and 10Gy and 6.9% for doses in excess of 12Gy.
This means that SRS can be safely employed only for tumors
at least 2–4mm away from the optic chiasm, depending on
size, position, and shape of the tumor, as well delivered dose
and radiosurgical treatment techniques.
By contrast, there is no restriction to the size of pituitary
adenoma suitable for SRT when a conventional fractionation
is used, since the delivered total doses are within tolerance of
normal brain structures, including the optic apparatus.
3. Efﬁcacy andToxicity of Irradiation
3.1. Stereotactic Radiosurgery. Results of 29 recent published
studies including 1215 patients with GH-secreting pituitary
adenomas treated with SRS are showed in Table 1 [23–51].
At a corrected median followup of 50.6 months (range 6–
114 months), the reported tumor growth control following
SRSis98%,rangingfrom92to100%.Avariablebiochemical
remission of disease ranging from 17% to 82% has been
reported, depending by the diﬀerent lengths of followup and
the criteria used to deﬁne the biochemical control of disease.
When glucose-suppressed plasma GH levels during OGTT
and normal age-corrected IGF-I values were used to deﬁne
the biochemical remission of acromegaly according to recent
criteria of endocrinologic cure [52], the 5-year hormonal
normalization observed in 9 studies reporting 528 patients
was 43% (range 15–60 months) [38, 42, 44–47]. Time to
response ranged from 12 to 66 months. GK SRS is the most
widely reported radiosurgical technique. Only few studies
report on the use of linac SRS for GH-secreting tumors,
although with a similar eﬃcacy when compared with GK
SRS.
In a retrospective analysis of 83 patients with acromegaly
treated with GK SRS at University of Milan San Raﬀaele
between 1994 and 2006, the reported actuarial biochemical
remissionrateswere30%,52%,and85%at3,5,and10years,
respectively [47]. Jezkov´ a et al. [41] in a series of 96 patients
reported hormonal remission rates of 45% at 3 years, 58% atInternational Journal of Endocrinology 3
Table 1: Summary of results of recent series on SRS for GH-secreting pituitary adenomas.
Authors patients
No
Type of
SRS
Total
dose Gy
followup
median
(months)
Tumor
control (%)
Hormone
normalization
(%)
Late toxicity (%)
Visual Hypopituitarism
Morange-Ramos et al.
[23] 15 GK SRS 28 20 NA 20 5 16
Lim et al. [24] 20 GK SRS 25 26 92.5 30 5 5
Landolt et al. [25] 16 GK SRS 25 17 NA 50 0 0
Kim et al. [26] 11 GK SRS 28.7 27 NA 35 0 0
Inoue et al. [27]1 2 G K S R S 2 1 >24 94 58 NA NA
Mokry et al. [28] 10 GK SRS 16 46 100 31 0 NA
Izawa et al. [29] 29 GK SRS 22.5 >6 100 41 0 0
Zhang et al. [30] 68 GK SRS 31 32 NA 40 1.3 4
Landolt et al. [31] 31 GK SRS 25 19.2 NA 69 NA NA
Ikeda et al. [32] 17 GK SRS 25 58 NA 82 0 0
Pollock et al. [33] 26 GK SRS 20 36 100 47 0 16
Swords et al. [34] 13 LINAC SRS 8–15 25 100 35 0 0
Choi et al. [35] 12 GK SRS 28.5 43 100 30 0 0
Attanasio et al. [36] 30 GK SRS 20 46 100 30 at 5 years 0 6.7
Jane et al. [37]6 4 G K S R S 1 5 >18 NA 36 0 28
Castinetti et al. [38] 82 GK SRS 26 49.5∗ NA 17 1.2 17
Gutt et al. [39] 44 GK SRS 23 22 100 48 NA NA
Kobayashi et al. [40] 67 GK SRS 18,9 63 100 17 11 15
Jezkov´ ae ta l .[ 41] 96 GK SRS 32 53.7 100 44 at 5 years 0 27.1
Voges et al. [42] 64 LINAC SRS 16,5 54.3 97 14 and 33 at 3
and 5 years 1.4 13 and 18 at 3
and 5 years
Petit et al. [43] 22 Proton SRS 20 CGE 75.6 100 59 0 38
Pollock et al. [44] 46 GK SRS 20 63 100 11 and 60 at 2
and 5 years 0 33 at 5 years
Vik-Mo et al. [45] 53 GK SRS 26.5 67 100 58 and 86 at 5
and 10 years 3.8 10 at 5 years
Jagannathan et al.
[46] 95 GK SRS 22 57 98 36 and 47 at 3
and 5 years 43 4
Losa et al. [47] 83 GK SRS 21,5 69 97 52 and 85 at 5
and 10 years 0 1 0a t1 0y e a r s
Ronchi et al. [48] 35 GK SRS 20 114 100 15 and 46 at 5
and 10 years 06 9
Wan et al. [49] 103 GK SRS 21,4 67 95 37 0 6
Hayashi et al. [50] 25 GK SRS 25.2 36 100 40 0 0
Iwai et al. [51] 26 GK SRS 20 84 96 17 and 47 at 5
and 10 years 08
Milker-Zabel et al.
[55] 20 FSRT 52.2 61 100 80 at 5 years 5 15
Colin et al. [56]3 1 ∗∗ FSRT 50.4 80 99 20 and 50 at 5
and 10 years 03 7
Minniti et al.[57]1 8 ∗∗ FSRT 45 39 98 50 at 5 years∗ 02 2
Imran et al. [58] 12 FSRT 50 28.5 92 33 0 8
Roug et al. [59] 34 FSRT 54 45 91 36 at 5 years NA 29
NA not assessed.
∗mean followup; ∗∗acromegalic patients included in series of FSRT for either secreting or non secreting pituitary tumors.4 International Journal of Endocrinology
5 years, and 57% at 8 years, respectively. Similar biochemical
remission rates in the range of 45–60% at 5 years have been
shown by others [44–46], although lower rates have been
reported in some series [36, 38, 42, 51].
Remission of disease after SRS has been associated with
pretreatment levels of GH and/or IGF-I levels in some series
[38, 41, 44, 47] similar to that reported after conventional RT
[7–10]. In a retrospective analysis of 46 consecutive patients
3-year and 5-year biochemical remission rates were 40%
and 90% for patients with IGF-I levels less than 2.25 times
the upper limit of normal and 23% and 38% with IGF-
I levels greater than 2.25 times the upper limit of normal,
respectively. Losa et al. [47] reported a median time for
remission of 37 months for patients with pretreatment GH
levels ≤7µg/liter as compared with 93 months for patients
with GH levels >7µg/liter. Although no relationship between
baseline hormonal levels and remission of acromegaly has
been reported in few series [36, 45], it seems reasonable
that patients with near-normal GH and IGF-I levels are
morelikelytoachievehormonalremissionthanpatientswith
markedly abnormal pretreatment levels.
Marginal doses of 15–34Gy have been employed for
the treatment of GH-secreting pituitary adenomas. In the
majority of studies, higher doses were not associated with
higher rate of remission or faster normalization of GH/IGF-
I levels. Thus, a marginal dose of about 20–25Gy seems
appropriate to achieve either tumor control or hormonal
normalization.
The concomitant use of somatostatin analogs at the
time of SRS as negative predictor of biochemical remission
remains matter of debate. Although in Landolt et al. [25]
and Pollock et al. [33], series the use of somatostatin analogs
at the time of SRS was correlated with a worse outcome,
other authors found no diﬀerences in the outcome between
patients who received somatostatin agonists at the time of
GK and those who did not. Although somatostatin analogs
withdrawal before SRS has gained an increase acceptance
in clinical practice, future prospective studies are needed to
elucidate the issue.
The reported overall rate of serious complications after
SRS is low (Table 1). The most commonly observed com-
plication following SRS for secreting adenomas was hypopi-
tuitarism, with an incidence ranging between 0 and 69%,
although hormonal function has not been systematically
evaluated in most studies. In a series of 39 patients with
acromegaly treated with GK SRS, a new pituitary deﬁcit
occurred in one-third of patients, with an actuarialincidence
of hypopituitarism of 10% at 2 years and 33% at 5 years,
respectively [27]. Jagannathan et al. [46] reported new
endocrine deﬁciencies in 34% of 95 patients treated with
GK SRS, and a similar incidence of hypopituitarism at 5
years has been observed in few other series [41, 45, 48].
Other treatment-related complications occur rarely after
SRS. Cranial neuropathies, brain radionecrosis, and carotid
artery stenosis have been reported infrequently following
SRS. Loeﬄer et al. [53]r e p o r t e dt w oc a s e so fs e c o n d a r y
brain tumors after SRS for a pituitary adenoma. The risk to
developanewtumorafterSRSappearstobesigniﬁcantlyless
than that seen following fractionated RT [54]; however, the
relatively short length of followup of most published series
does not allow for any deﬁnitive conclusion.
A recent experience of proton SRS showed a biochemical
remission in 50% of 22 patients with GH-secreting pituitary
adenomas, with a median time to complete response of 30.5
months [43]. One-third of patients developed at least one
newpituitarydeﬁciency,requiringmedicaltherapy.Basedon
this preliminary experience, the use of proton SRS does not
seem to oﬀer clinical advantages when compared to photons
SRS.
3.2. Fractionated Stereotactic Radiotherapy. Five studies
report on the use of FSRT in 115 patients with GH-secreting
pituitary adenomas [54–59]( Table 1). At a median corrected
followup of 54 months ranging from 28 to 80 months,
the reported tumor control was 97%. The median and 5-
year biochemical remission of disease were 40% and 42%,
being similar to the best reported rates of large studies of
conventional RT and SRS. Milker-Zabel et al. [55]r e p o r t e d
the normalization of elevated GH level in 70% of 20
acromegalic patients at a median of 26 months, with 5-
year local and hormonal control rates of 100% and 80%,
respectively.Inaseriesof18patientswithacromegalytreated
withFSRTatRoyalMarsdenHospital,biochemicalremission
was achieved in 35% after a median followup of 39 months
[54]. Actuarial normalization of GH/IGF-I levels was 20%
at 3 years and 50% at 5 years. At a median followup of 30
months, Roug et al. [59] observed biochemical remission of
disease, as deﬁned by suppressed GH at OGTT and normal
IGF-Ilevelsadjustedforage,in30%of34patientswithactive
acromegaly, being 24%, 38%, and 64% after 1, 3, and 5 years,
respectively.
A low-radiation-induced toxicity has been reported after
FSRT, even in the case of large tumors involving the optic
apparatus. Hypopituitarism has been reported in 8–37% of
patients at median followup ranging from 28 to 82 months,
whereas the reported incidence of optic neuropathy is 1–5%.
N oc a s e so fC V Aa n ds e c o n dt u m o r sh a v eb e e nr e p o rt e da f t e r
FSRT. Since the incidence of such complications increases
with time, large series and longer followups need to demon-
strate the potential clinical advantages of treating less normal
brain at high doses achieved with the use of the stereotactic
techniques. Similarly, because of the lack of formal cognitive
function testing and quality of life assessment after FSRT, the
potential superiority of stereotactic techniques as compared
with 3D conformal remains to be clariﬁed.
Initial experiences with the application of CyberKnife in
treating patients with acromegaly are promising [60, 61].
In a report of nine patients with acromegaly treated with
CyberKnife to doses of 18–24Gy in one to three fractions,
biochemical remission was observed in 4 patients at a mean
followup of 25.4 months [61]. Whilst these results are
promising, the short followup and the small number of
patients do not permit any conclusion about the low risk of
optic neuropathy in patients treated with hypofractionated
regimens. When fractionation is thought to be safer than
SRS, conventional fractionation should be considered on the
basis of its proven eﬃcacy and safety.International Journal of Endocrinology 5
4.FSRSversusSRT
There is much debate about the relative eﬃcacy of SRS
and SRT. Currently reported results suggest similar results
in terms of tumor control and biochemical remission of
acromegaly.
A faster decline of serum GH concentration after GK SRS
as compared with FSRT has been reported by some authors
[25, 62]. In a small series of 16 patients with acromegaly,
Landolt et al. [25] reported mean time to normalization
of GH/IGF-I levels of 1.4 years in the group treated with
the GK and 7.1 years in the group treated with FSRT.
Mitsumori et al. [62] reported mean time to hormone
normalization of 8.5 and 18 months in patients treated
with SRS and FSRT, respectively. In contrast, recent series
have showed a time to hormonal normalization following
SRS of 30–66 months [36, 38, 41, 44–47] similar to that
reported after fractionated RT [55, 57, 59] and suggesting
that time to hormonal normalization is more dependent on
preirradiation GH/IGF-I levels than diﬀerences in radiation
techniques. So far, the superiority of SRS in terms of time
to hormonal normalization remains to be demonstrated.
Data from stereotactic series suggest that the incidence of
hypopituitarism after SRS is lower than that reported after
fractionated RT; however, this may reﬂect diﬀerent patient
selection and length of followups, and large prospective
studies are needed to clarify this issue.
In absence of comparative studies, the choice of the
radiation technique is based on tumor characteristics. SRS
is usually oﬀered to patients with relatively small adenomas
less than 3cm in size and away more than 2-3mm from
the optic chiasm. FSRT should be preferred in patients with
large tumors in close proximity of optic apparatus, since the
treatment is delivered within the radiation tolerance limits of
cranial nerves, including the optic apparatus.
5. Conclusion
SRS and FSRT represent eﬀective treatment modalities of
irradiation for patients with persistent active GH/IGF-I
hypersecretion after surgery and/or during medical therapy,
providing a comparable high rates of tumor control and
endocrinological remission with low morbidity. Treating less
normal brain by higher radiation doses is a clear technical
improvement of modern RT which translates into clinical
beneﬁt in terms of reduction of late eﬀects of radiation.
In most centres, SRS is a convenient approach for patients
with relatively small residual GH-secreting tumors, while
FSRT is usually reserved to patients with larger tumors
not amenable to SRS. Prospective studies comparing SRS
with FSRT would be of value to evaluate the long-term
eﬃcacy and toxicity of the techniques. Eﬃcacy and toxicity
of hypofractionated treatment schedules need to be explored
in future studies.
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